Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC

Abstract

Introduction: The role of direct acting antivirals (DAAs) for hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) recurrence is a source of great debate. Current evidence is unable to determine whether DAAs increases or decreases risk of recurrence. However, it has not been investigated the role of DAAs in patients undergoing orthotopic liver transplantation (OLT) for HCC. As a post-OLT recurrence is a deadly event, we compared the risk of recurrence and the overall survival (OS) of patients treated with DAA and obtaining SVR before OLT with an historical cohort of patients transplanted for HCC before the arrival of DAAs.